Sign up USA
Proactive Investors - Run By Investors For Investors

Akers Biosciences Inc breakthrough device granted US patent

The protection covers the company’s PIFA Rapid Assay and the unique methods it uses for detecting platelet factor 4 antibodies.
Stylised picture of patent agreement plus padlock.
The US Patent and Trademark Offices has given its sign-off.

Akers Biosciences Inc (NASDAQ:AKER, LON:AKR) has been granted a US patent for the technology at the heart of a test that detects an allergy to the blood thinning drug Heparin.

The protection covers the company’s PIFA Rapid Assay and the unique methods it uses for detecting platelet factor 4 antibodies.

"This patent is particularly important because it protects the antigen that gives our tests their superior accuracy,” said chairman and co-founder Raymond Akers.

“With published studies that demonstrate that our tests never deliver a false positive result, we believe them to be the most accurate available way to rule out HIT."

The device takes 10 minutes to assess for heparin-induced thrombocytopenia, or HIT, where the blood clots instead of thins.

The process of assessing a patient for HIT requires expensive blood tests that can take several days to turn around.

The diagnostic is the only one of its kind to receive sign off from America’s all-powerful Food & Drug Administration.

Ian_55ae0ddd437b7.jpg


Register here to be notified of future AKR Company articles
View full AKR profile

Akers Biosciences, Inc. Timeline

Related Articles

Stem Cells
March 30 2017
WideCells is aiming to be a major supporting player through its development of a stem cell storage business and, having only listed in London last July, its newsflow so far looks to be pointing the way
picture of pregnant woman
February 07 2017
MyLotus has been developed for women who have been trying to conceive for six months or more.
Harley Street London street sign
May 27 2016
The cancer treatment specialist has received funding to bring its breakthrough therapy to London.
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use